Patents by Inventor Zoltan Kiss
Zoltan Kiss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100279411Abstract: Embodiments of the present invention include the use of placental alkaline phosphatase alone or in combination with human transferrin and, optionally, human ?1-antitrypsin to enhance the proliferation and survival of transplanted stem cells and stem cell-derived progenitor cells.Type: ApplicationFiled: July 9, 2010Publication date: November 4, 2010Applicant: ZOLTAN LABORATORIES LLCInventor: Zoltan Kiss
-
Patent number: 7790685Abstract: Embodiments of the present invention include the use of placental alkaline phosphatase alone or in combination with human transferrin and, optionally, human ?1-antitrypsin to enhance the proliferation and survival of transplanted stem cells and stem cell-derived progenitor cells.Type: GrantFiled: August 11, 2008Date of Patent: September 7, 2010Assignee: Zoltan Laboratories LLCInventor: Zoltan Kiss
-
Patent number: 7786082Abstract: Embodiments of the present invention include the use of placental alkaline phosphatase and other members of the alkaline phosphatase family alone or in combination with human transferrin and, optionally, human ?1-antitrypsin to enhance the proliferation and survival of adult or embryonic stem cells and stem cell-derived progenitor cells in vivo.Type: GrantFiled: August 11, 2008Date of Patent: August 31, 2010Assignee: Zoltan Laboratories LLCInventor: Zoltan Kiss
-
Publication number: 20100215635Abstract: Embodiments of the present invention include the use of heterocyclic trialkyl ammonium-containing compounds alone or in combination with alkaline phosphatase or other weight loss-inducing drugs or methods to reduce or reverse excess weight gain and obesity as well as reduce the risk of development and help treatment of diseases and unhealthy conditions related to overweight and obesity.Type: ApplicationFiled: February 23, 2009Publication date: August 26, 2010Inventor: Zoltan Kiss
-
Patent number: 7781423Abstract: Embodiments of the present invention include the use of heterocyclic trialkyl ammonium-containing compounds to promote regeneration of bone marrow from endogenous or exogenous stem/progenitor cells and to normalize blood cell and platelet counts.Type: GrantFiled: August 29, 2008Date of Patent: August 24, 2010Assignee: CanCure Laboratories, LLCInventor: Zoltan Kiss
-
Publication number: 20100158888Abstract: Embodiments of the present invention relate to the use of placental alkaline phosphatase, and other members of the alkaline phosphatase family, to enhance protein synthesis in the muscle as well as the survival of non-cancerous differentiated cells in the muscle, adipose and other tissues. The ability of alkaline phosphatase to selectively enhance the survival of healthy cells and increase protein synthesis has many therapeutic applications. The use of alkaline phosphatase may prevent the loss of body weight and muscle mass typically experienced by diseased (such as cancer) or aging patients, or developing fetuses subjected to harmful conditions, or by patients who are treated with a toxic therapy including chemotherapy.Type: ApplicationFiled: March 2, 2010Publication date: June 24, 2010Applicant: ZOLTAN LABORATORIES LLCInventor: Zoltan Kiss
-
Publication number: 20100137557Abstract: Compositions and methods for decreasing the viability of cells, particularly aberrant non-healthy cells, and most particularly cancer cells, are disclosed. The primary agent that causes cell death is a toxic metal atom or ion. Embodiments of the invention provide compositions and methods to ensure that the toxic metal is directed to the desired cell or tissue. In one embodiment, the metal is bound to a sulfur-rich peptide or protein carrier containing a targeting moiety. Such metal-protein complex is targeted to the selected cells or tissues to enrich the cell or tissue site with the metal-containing peptide or protein molecules followed by administering a dithiocarbonyl which carries the metal from the protein inside the cells to induce cell death.Type: ApplicationFiled: October 22, 2009Publication date: June 3, 2010Applicant: CanCure Laboratories LLCInventor: Zoltan KISS
-
Patent number: 7718170Abstract: Compositions of human proteins, methods and regimens for reducing the occurrence and growth of skin cancer, including melanoma, are provided. The methods include steps of administering topically on the skin tumor or a skin cancer-free area of compositions containing therapeutically effective amounts of human alkaline phosphatase, transferrin and ?1-antitrypsin. In some embodiments, the composition is topically administered and includes all three proteins. Alkaline phosphatase, alone or in combination with transferrin and ?1-antitrypsin can also be administered by injection with or without simultaneous or sequential topical administration. Administration of compositions topically and/or by injection can be part of a more complex cancer therapy including chemotherapy, radiotherapy, surgery, and electrochemotherapy.Type: GrantFiled: August 21, 2006Date of Patent: May 18, 2010Assignee: Essential Skincare, LLCInventor: Zoltan Kiss
-
Patent number: 7695714Abstract: Embodiments of the present invention relate to the use of placental alkaline phosphatase, and other members of the alkaline phosphatase family, to enhance protein synthesis in the muscle as well as the survival of non-cancerous differentiated cells in the muscle, adipose and other tissues. The ability of alkaline phosphatase to selectively enhance the survival of healthy cells and increase protein synthesis has many therapeutic applications. The use of alkaline phosphatase may prevent the loss of body weight and muscle mass typically experienced by diseased (such as cancer) or aging patients, or developing fetuses subjected to harmful conditions, or by patients who are treated with a toxic therapy including chemotherapy.Type: GrantFiled: August 8, 2006Date of Patent: April 13, 2010Assignee: Zoltan Laboratories LLCInventor: Zoltan Kiss
-
Publication number: 20100048668Abstract: A class of compounds commonly containing a trialkylammonium group have been synthesized and characterized as anticancer compounds. They can be used alone or in combination with other therapies to treat cancer and other cell proliferative diseases. Representative compounds of this class, N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide and N,N-diethyl-N-allyl-3-(2-methyl-9H-thioxanthen-9-ylidene)-propane-1-aminium bromide, were shown in various tumor models to decrease tumor volume, enhance the effects of other chemotherapeutic agents including cisplatin, reduce chemotherapy-induced loss of body weight, and increase survival of animals co-treated with toxic amounts of cisplatin. These compounds had even greater effects on tumor volume, body weight, and survival when administered together with the human protein placental alkaline phosphatase.Type: ApplicationFiled: October 2, 2009Publication date: February 25, 2010Applicant: CanCure Laboratories, LLCInventor: Zoltan Kiss
-
Patent number: 7655620Abstract: Compositions and methods for decreasing the viability of cells, particularly aberrant non-healthy cells, and most particularly cancer cells, are disclosed. The primary agent that causes cell death is a toxic metal atom or ion. Embodiments of the invention provide compositions and methods to ensure that the toxic metal is directed to the desired cell or tissue. In one embodiment, the metal is bound to a sulfur-rich peptide or protein carrier containing a targeting moiety. Such metal-protein complex is targeted to the selected cells or tissues to enrich the cell or tissue site with the metal-containing peptide or protein molecules followed by administering a dithiocarbonyl which carries the metal from the protein inside the cells to induce cell death.Type: GrantFiled: June 22, 2006Date of Patent: February 2, 2010Assignee: Cancure Laboratories, LLCInventor: Zoltan Kiss
-
Publication number: 20100022617Abstract: A class of compounds commonly containing a trialkylammonium group have been synthesized and characterized as anticancer compounds. A representative of this class, N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide (CCDTHT) was shown in various tumor models to decrease tumor volume, enhance the effects of other chemotherapeutic agents including cisplatin, reduce chemotherapy-induced loss of body weight, and increase survival of animals co-treated with toxic amounts of cisplatin. CCDTHT had even greater effects on tumor volume, body weight, and survival when administered to animals together with the human protein placental alkaline phosphatase. These trialkylammonium group-containing compounds and alkaline phosphatases, particularly in combination with each other and other therapies, may be used to treat cancer and other cell proliferative diseases.Type: ApplicationFiled: July 13, 2009Publication date: January 28, 2010Applicant: CanCure Laboratories, LLCInventor: Zoltan Kiss
-
Publication number: 20090317372Abstract: Embodiments of the present invention include the in vivo use of a family of heterocyclic compounds containing a quaternary ammonium group as exemplified by the thioxanthone and thioxanthene compounds [3-(3,4-dimethyl-9-oxo-9H-thioxanthen-2-yloxy)-2-hydroxypropyl]trimethylammonium chloride, or CCcompound1, N,N,-diethyl-N-methyl-2-[9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide, or CCcompound3, and N,N,N-trimethyl-3-(9H-thioxanthen-9-ylidene)-propane-1-aminium iodide, or CCcompound19 to reduce higher than normal blood glucose level within or close to the normal range in subjects with insulin resistance, hyperglycemia, and diabetes thereby also reducing or preventing associated diseases, complications, and pathological states.Type: ApplicationFiled: February 27, 2009Publication date: December 24, 2009Inventor: Zoltan Kiss
-
Patent number: 7589083Abstract: A class of compounds commonly containing a trialkylammonium group have been synthesized and characterized as anticancer compounds. A representative of this class, N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide (CCDTHT) was shown in various tumor models to decrease tumor volume, enhance the effects of other chemotherapeutic agents including cisplatin, reduce chemotherapy-induced loss of body weight, and increase survival of animals co-treated with toxic amounts of cisplatin. CCDTHT had even greater effects on tumor volume, body weight, and survival when administered to animals together with the human protein placental alkaline phosphatase. These trialkylammonium group-containing compounds and alkaline phosphatases, particularly in combination with each other and other therapies, may be used to treat cancer and other cell proliferative diseases.Type: GrantFiled: July 19, 2006Date of Patent: September 15, 2009Assignee: Cancure Laboratories, LLCInventor: Zoltan Kiss
-
Patent number: 7557081Abstract: Methods of using alpha-1-acid glycoprotein, or an active derivative, to modulate the blood glucose level in mammals, particularly humans, is described. A therapeutically effective amount of alpha-1-acid glycoprotein is administered to a patient afflicted with Type 1 or Type 2 diabetes to lower the blood glucose level. An anti-diabetic medicament, particularly insulin, may also be administered in combination with alpha-1-acid glycoprotein. The invention also provides a treatment regimen by periodically administering alpha-1-acid glycoprotein and further provides a method of mitigating the inhibitory effect of an acute phase protein on the action of insulin.Type: GrantFiled: May 27, 2005Date of Patent: July 7, 2009Assignee: Essential SkinCare, LLCInventor: Zoltan Kiss
-
Publication number: 20090130080Abstract: The present invention provides methods for using human placental alkaline phosphatase or an active derivative to reduce blood glucose level in a mammal. Treatment regimens provided by the invention may be used to control Type 1 and Type 2 forms of diabetes in humans. The methods and treatment regimens may be effective to maintain the human's blood glucose level below about 10 mM, and preferably within the normal range of 4 mM to 7 mM. The methods and treatment regimens may be used in combination with administration of known anti-diabetic medicaments. Also provided by the invention is a method for inducing weight loss or reducing an expected weight gain caused by or associated with obesity or Type 2 diabetes. The invention further provides a preparation for administration to a human, the preparation comprising homogeneous purified human placental alkaline phosphatase in a physiologically acceptable carrier.Type: ApplicationFiled: January 28, 2009Publication date: May 21, 2009Applicant: Zoltan Laboratories LLCInventor: Zoltan Kiss
-
Patent number: 7501116Abstract: The present invention provides methods for using human placental alkaline phosphatase or an active derivative to reduce blood glucose level in a mammal. Treatment regimens provided by the invention may be used to control Type 1 and Type 2 forms of diabetes in humans. The methods and treatment regimens may be effective to maintain the human's blood glucose level below about 10 mM, and preferably within the normal range of 4 mM to 7 mM. The methods and treatment regimens may be used in combination with administration of known anti-diabetic medicaments. Also provided by the invention is a method for inducing weight loss or reducing an expected weight gain caused by or associated with obesity or Type 2 diabetes. The invention further provides a preparation for administration to a human, the preparation comprising homogeneous purified human placental alkaline phosphatase in a physiologically acceptable carrier.Type: GrantFiled: September 30, 2005Date of Patent: March 10, 2009Assignee: Zoltan LaboratoriesInventor: Zoltan Kiss
-
Publication number: 20090030066Abstract: Embodiments of the present invention include the in vivo and in vitro use of a family of anticancer heterocyclic compounds containing a quaternary ammonium group as exemplified by the thioxanthone and thioxanthene compounds [3-(3,4-dimethyl-9-oxo-9H-thioxanthen-2-yloxy)-2-hydroxypropyl]trimethylammonium chloride, or CCompound1, N,N,-diethyl-N-methyl-2-[9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide, or CCompound3, and N,N,N-trimethyl-3-(9H-thioxanthen-9-ylidene)-propane-1-aminium iodide, or CCompound19 to maintain and increase viability of normal endocrine and exocrine pancreatic cells under pathological conditions, such as type 1 and type 2 diabetes, pancreatitis, pancreatic cancer, or during and after islet transplant, or in preparation for transplant of isolated islet cells via (i) direct contact with these cells, and/or via (ii) enhancing survival and proliferation of endogenous or transplanted adult stem cells, and/or via (iii) reducing viability of pancreatic cancer cells.Type: ApplicationFiled: July 23, 2008Publication date: January 29, 2009Applicant: Zoltan Laboratories LLCInventor: Zoltan Kiss
-
Publication number: 20090004136Abstract: Embodiments of the present invention include the use of heterocyclic trialkyl ammonium-containing compounds to promote regeneration of bone marrow from endogenous or exogenous stem/progenitor cells and to normalize blood cell and platelet counts.Type: ApplicationFiled: August 29, 2008Publication date: January 1, 2009Applicant: Zoltan Laboratories LLCInventor: Zoltan Kiss
-
Publication number: 20080299106Abstract: Embodiments of the present invention include the use of placental alkaline phosphatase and other members of the alkaline phosphatase family alone or in combination with human transferrin and, optionally, human ?1-antitrypsin to enhance the proliferation and survival of adult or embryonic stem cells and stem cell-derived progenitor cells in vivo.Type: ApplicationFiled: August 11, 2008Publication date: December 4, 2008Applicant: Zoltan Laboratories LLCInventor: Zoltan Kiss